Setting

Europe Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

Published: 26 Oct 2020 | Report Code: 10247758 | Pages: 116

Europe pharmaceutical contract manufacturing market accounted for $24.4 billion in 2019 and will grow by 6.0% annually over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity. Highlighted with 38 tables and 53 figures, this 116-page report “Europe Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country. Based on Category, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Product, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Active Pharmaceutical Ingredients (API) • Branded API Manufacturing • Generic API Manufacturing Finished Dosage Formulations (FDF) • Solid Dosage • Oral Liquids • Parenteral/Injectables • Other FDFs Secondary Packaging Based on Phase, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Clinical Manufacturing • Commercial Manufacturing Based on Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Sterile Products • Non-Sterile Products Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of Europe Market by Category	41
3.1 Market Overview by Category	41
3.2 Pharmaceutical Industry	43
3.3 Biopharmaceutical Industry	44
4 Segmentation of Europe Market by Product	45
4.1 Market Overview by Product	45
4.2 Active Pharmaceutical Ingredients (API)	47
4.2.1 Branded API Manufacturing	48
4.2.2 Generic API Manufacturing	49
4.3 Finished Dosage Formulations (FDF)	50
4.3.1 Solid Dosage	52
4.3.2 Oral Liquids	53
4.3.3 Parenteral/Injectables	54
4.3.4 Other FDFs	55
4.4 Secondary Packaging	56
5 Segmentation of Europe Market by Phase	57
5.1 Market Overview by Phase	57
5.2 Clinical Manufacturing	59
5.3 Commercial Manufacturing	60
6 Segmentation of Europe Market by Type	61
6.1 Market Overview by Type	61
6.2 Sterile Products	63
6.3 Non-Sterile Products	64
7 Segmentation of Europe Market by Therapeutic Application	65
7.1 Market Overview by Therapeutic Application	65
7.2 Infectious Diseases	67
7.3 Oncology	68
7.4 Metabolic Disorders	69
7.5 Cardiovascular Disorders	70
7.6 Central Nervous System	71
7.7 Pulmonary Disorders	72
7.8 Gastrointestinal Disorders	73
7.9 Other Therapeutic Applications	74
8 European Market 2019-2030 by Country	75
8.1 Overview of European Market	75
8.2 Germany	78
8.3 UK	80
8.4 France	82
8.5 Spain	84
8.6 Italy	86
8.7 Russia	88
8.8 Rest of European Market	90
9 Competitive Landscape	92
9.1 Overview of Key Vendors	92
9.2 New Product Launch, Partnership, Investment, and M&A	96
9.3 Company Profiles	97
Aenova Group	97
Baxter BioPharma Solutions	99
Boehringer Ingelheim	100
Catalent Inc.	101
Famar S.A.	102
Hospira, Inc.	103
Jubilant Life Sciences Ltd.	104
Lonza Group	105
Patheon Inc.	106
Pfizer CentreSource	107
Recipharm AB	108
Vetter Pharma International GmbH	109
10 Investing in Europe Market: Risk Assessment and Management	110
10.1 Risk Evaluation of Europe Market	110
10.2 Critical Success Factors (CSFs)	113
Related Reports and Products	116
List Of Tables

Table 1.  Snapshot of Europe Pharmaceutical Contract Manufacturing Market, 2019-2030	18
Table 2. Growth Rate of World Real GDP, 2017-2021	22
Table 3.  Main Product Trends and Market Opportunities in Europe Pharmaceutical Contract Manufacturing Market	32
Table 4. Europe Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, $ bn	41
Table 5. Europe Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	45
Table 6. Europe Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn	47
Table 7. Europe Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn	51
Table 8. Europe Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	57
Table 9. Europe Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, $ bn	61
Table 10. Europe Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	65
Table 11. Europe Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, $ bn	77
Table 12. Germany Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	79
Table 13. Germany Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	79
Table 14. Germany Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	79
Table 15. UK Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	81
Table 16. UK Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	81
Table 17. UK Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	81
Table 18. France Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	83
Table 19. France Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	83
Table 20. France Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	83
Table 21. Spain Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	85
Table 22. Spain Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	85
Table 23. Spain Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	85
Table 24. Italy Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	87
Table 25. Italy Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	87
Table 26. Italy Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	87
Table 27. Russia Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	89
Table 28. Russia Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	89
Table 29. Russia Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	89
Table 30. Pharmaceutical Contract Manufacturing Market in Rest of Europe by Country, 2019-2030, $ bn	91
Table 31. Breakdown of Europe Market by Key Vendor, 2019, %	94
Table 32. Aenova Group: Company Snapshot	97
Table 33. Aenova Group: Business Segmentation	97
Table 34. Aenova Group: Product Portfolio	98
Table 35. Aenova Group: Revenue, 2016-2018, $ bn	98
Table 36. Aenova Group: Recent Developments	98
Table 37.  Risk Evaluation for Investing in Europe Market, 2019-2030	111
Table 38. Critical Success Factors and Key Takeaways	114
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Europe Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn	20
Figure 6. Impact of COVID-19 on Business	24
Figure 7. Primary Drivers and Impact Factors of Europe Pharmaceutical Contract Manufacturing Market	26
Figure 8. Primary Restraints and Impact Factors of Europe Pharmaceutical Contract Manufacturing Market	29
Figure 9. Investment Opportunity Analysis	33
Figure 10. Porter’s Fiver Forces Analysis of Europe Pharmaceutical Contract Manufacturing Market	36
Figure 11. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue	42
Figure 12. Europe Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)	42
Figure 13. Europe Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn	43
Figure 14. Europe Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn	44
Figure 15. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue	46
Figure 16. Europe Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%)	46
Figure 17. Europe Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn	47
Figure 18. Europe Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn	48
Figure 19. Europe Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn	49
Figure 20. Europe Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn	50
Figure 21. Europe Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn	52
Figure 22. Europe Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn	53
Figure 23. Europe Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn	54
Figure 24. Europe Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn	55
Figure 25. Europe Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn	56
Figure 26. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue	58
Figure 27. Europe Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%)	58
Figure 28. Europe Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn	59
Figure 29. Europe Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn	60
Figure 30. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue	62
Figure 31. Europe Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%)	62
Figure 32. Europe Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn	63
Figure 33. Europe Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn	64
Figure 34. Breakdown of Europe Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue	66
Figure 35. Europe Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)	66
Figure 36. Europe Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn	67
Figure 37. Europe Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn	68
Figure 38. Europe Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn	69
Figure 39. Europe Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn	70
Figure 40. Europe Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn	71
Figure 41. Europe Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn	72
Figure 42. Europe Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn	73
Figure 43. Europe Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn	74
Figure 44. Breakdown of European Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue	76
Figure 45. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	77
Figure 46.  Pharmaceutical Contract Manufacturing Market in Germany, 2019-2030, $ bn	78
Figure 47.  Pharmaceutical Contract Manufacturing Market in UK, 2019-2030, $ bn	80
Figure 48.  Pharmaceutical Contract Manufacturing Market in France, 2019-2030, $ bn	82
Figure 49.  Pharmaceutical Contract Manufacturing Market in Spain, 2019-2030, $ bn	84
Figure 50.  Pharmaceutical Contract Manufacturing Market in Italy, 2019-2030, $ bn	86
Figure 51.  Pharmaceutical Contract Manufacturing Market in Russia, 2019-2030, $ bn	88
Figure 52.  Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030, $ bn	90
Figure 53. Growth Stage of Europe Pharmaceutical Contract Manufacturing Industry over the Forecast Period	92
Key Players (this may not be a complete list and extra companies can be added upon request): 
Aenova Group	
Baxter BioPharma Solutions	
Boehringer Ingelheim	
Catalent Inc.	
Famar S.A.	
Hospira, Inc.	
Jubilant Life Sciences Ltd.	
Lonza Group	
Patheon Inc.	
Pfizer CentreSource	
Recipharm AB	
Vetter Pharma International GmbH